Reactive Arthritis
8
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Rheumatology Patient Registry and Biorepository
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Monitoring of Inflammatory Conditions
Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD
Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy Adults
Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19
Study of Long-Term Antibiotic Treatment in Reactive Arthritis
New Immunomodulatory Therapy Strategies in Chronic Reactive Arthritis